

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	1005,393
				Filed	August 20, 2004
				First Named Inventor	Mitsuaki KUWANO
				Group Art Unit	1615
				Examiner Name	Suezu Ellis
Sheet	1	of	2	Attorney Docket Number	04561/HG

### U.S. PATENT DOCUMENTS

Exam. Inits <sup>*</sup>	Cite No <sup>1</sup>	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

### FOREIGN PATENT DOCUMENTS

Exam Inits <sup>*</sup>	Cit e No <sup>1</sup>	Offc <sup>3</sup>	Document Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevan t Portion	T <sup>6</sup>
/S.E./		JP	8-176016	A	UNIV. OF MIAMI	07-09-1996		*
/S.E./		JP	2002-326962	A	SANTEN PHARM. CO.	11-15-2002		**
/S.E./		JP	2000-247871	A	SANTEN PHARM. CO.	09-12-2000		*
/S.E./		EP	1 279 406	A1	SANTEN PHARM. CO.	01-29-2003		

Examiner Signature	/Suezu Ellis/	Date Considered	03/27/2008
-----------------------	---------------	--------------------	------------

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Place a check here if English translation is attached.

DATE MAILED: NOVEMBER 9, 2004

\*English-language translation enclosed

\*\*EP 1 297 406 is a related family member of JP 2002-326962

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/505,393
				Filing Date	August 20, 2004
				First Named Inventor	Mitsuaki KUWANO
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	04561/HG
<b>OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
/S.E./		Yutaka NAKANO, "Ryokunaisho Shujutsu to 5-Fluorouracil (5-FU)", Rinsho Ganka, Vol. 43, No. 13, pp. 1929-1933 (1989).			0
/S.E./		David MAURICE, "Review: Practical Issues in Intravitreal Drug Delivery", <u>Journal of Ocular Pharmacology and Therapeutics</u> , Vol. 17, No. 4 (2001), 393-401.			
/S.E./		Michael BARZA et al., "Intraocular Levels of Cefamandole Compared with Cefazolin after Subconjunctival Injection in Rabbits", Vol. 18, No. 3 (1979), pp. 250-255.			
/S.E./		Tsutomu YASUKAWA et al., "Targeted Delivery of Anti-Angiogenic Agent TNP-470 Using Water-Soluble Polymer in the Treatment of Choroidal Neovascularization", Vol. 40, No. 11, (1999), pp. 2690-2696.			
Examiner Signature		/Suezu Ellis/		Date Considered	03/27/2008

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

**DATE MAILED: NOVEMBER 9, 2004**

**\*English-language abstract enclosed.**